China’s 2022 NRDL readout

Pharmaceutical Executive

7 February 2023 - Despite the twists and turns, 2022 turned out to be a banner year for National Reimbursement Drug List’s new inclusions—and with welcomed upgrades to bidding and renewal rules.

The 2022 National Reimbursement Drug List processes got off to a good start in June 2022 as planned but had a few sputters along the way.

Read Pharmaceutical Executive article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , Listing , Market access , China